TNFSF15 and MIA Variant Associated with Immunotherapy and Prognostic Evaluation in Esophageal Cancer.
Jun YouJiaojiao BianJian ChenTianqin XiaAilu DengMing ZhangYiChen LiaoHuling WenZhengmin XuPublished in: Journal of oncology (2023)
In summary, IL17C, TNFSF15, and MIA may act as biomarkers for prognosis in moderately and poorly differentiated ESCAs, and they may be used as predictive genes of immunotherapy associated with CD8+ T cell and Tregs invasion in ESCAs.